Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

cal

remission in adult and pediatric patients with moderately to severely

active CD who have had an inadequate response to conventional therapy.

-- Reducing the number of draining enterocutaneous and rectovaginal

fistulas and maintaining fistula closure in adult patients with

fistulizing CD.

-- Reducing signs and symptoms, inducing and maintaining clinical

remission and mucosal healing, and eliminating corticosteroid use in

patients with moderately to severely active UC who have had an

inadequate response to conventional therapy.

-- Reducing signs and symptoms of active arthritis, inhibiting the

progression of structural damage and improving physical function in

patients with PsA.

-- Treatment of adult patients with chronic severe plaque PsO who are

candidates for systemic therapy and when other systemic therapies are

medically less appropriate.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

Important Safety Information

There are reports of serious infections, including tuberculosis (TB), sepsis and pneumonia. Some of these infections have been fatal. Tell your doctor if you have had recent or past exposure to people with TB. Your doctor will evaluate you for TB and perform a TB test. If you have latent (inactive) TB, your doctor should begin TB treatment before you start REMICADE. REMICADE can lower your ability to fight infections, so if you are prone to or have a h
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Luoxis Diagnostics, Inc. , ... (NYSE MKT: AMPE), today announced an upcoming presentation ... the American Academy of Surgical Trauma (AAST) and ... Philadelphia, Pennsylvania that will be ... results from a recently completed five-year prospective clinical ...
(Date:8/18/2014)... Mass. and NAGOYA, Japan ... (NYSE: BSX ) and ASAHI INTECC (Securities ... and Nagoya Stock Exchange) have formalized plans to develop ... joint project focuses on creating a device intended to ... The FFR market is an emerging field in interventional ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Anthem Blue Cross and Blue Shield in ... transparency initiative beyond major metro areas into the ... and everywhere in between can now access Anthem ... cost information for 59 specific medical procedures performed ...
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
Cached Medicine Technology:Anthem Blue Cross Blue Shield Introduces Cost Disclosure Tool Throughout Colorado 2Anthem Blue Cross Blue Shield Introduces Cost Disclosure Tool Throughout Colorado 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:8/19/2014)... Kentucky Markey Cancer Center researchers will provide a simple, free ... require testing for a genetic mutation. , Gliomas a ... are the most common and deadly form of brain ... brain cancer cases. In some of these cases, patients have ... mutation and patients who have this tend to survive ...
(Date:8/19/2014)... Hartford/VA Scholars Program has selected three geriatric ... provides career development and mentorship for projects that ... veterans, but for all older adults. , The ... physical activity among veterans, transitions from VA nursing ... disorder in older veterans. The Hartford/VA Geriatric Scholars ...
(Date:8/19/2014)... 2014 United Benefit Advisors (UBA), ... is pleased to announce Sihle Insurance Group as ... provides a single solution for insurance, financial services, ... needs. With a focus on commercial and personal ... insurance solutions, and payroll services, they are able ...
(Date:8/19/2014)... Utah (PRWEB) August 19, 2014 ... Solution, published a new guide on compliance and ... Benefits, small businesses want to offer employee health ... insurance is unsustainable. Additionally, there are new advantages ... guaranteed-issue, and lower costs. , The new ...
(Date:8/19/2014)... Respected Dallas Plastic Surgeon ... nationwide to feature one of the most advanced ... UltraShape. UltraShape uses ultrasound waves to selectively breakdown ... , The UltraShape System, by Syneron Medical, is ... targets subcutaneous fat, while keeping the surrounding skin ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors Welcomes New Partner Firm Sihle Insurance Group 2Health News:United Benefit Advisors Welcomes New Partner Firm Sihle Insurance Group 3Health News:Dallas Plastic Surgeon Dr. Benjamin Bassichis is Among the First to Offer UltraShape for Non-Surgical Liposuction 2Health News:Dallas Plastic Surgeon Dr. Benjamin Bassichis is Among the First to Offer UltraShape for Non-Surgical Liposuction 3
... ... QT Beat-to-Beat(sm) Studies , ... Rochester, N.Y. (PRWEB) March 11, 2010 -- iCardiac Technologies, Inc., a leader in ... pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. iCardiac will provide ...
... ... last three years fundraising to send life-saving bed nets to families in ... grassroots campaign to prevent malaria in Africa, the leading killer of children ... and plans to raise $50,000 by the time he starts college. This ...
... ... Plunge, a benefit for the Special Olympics. , ... Salt Lake City, UT (PRWEB) March 11, 2010 -- Bullfrog International, makers ... Pelican Bay Marina in Saratoga Springs, Utah and hosted by the Saratoga Police Department. Bullfrog ...
... ... from a national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary ... each year. , ... Washington, D.C. (PRWEB) March 11, 2010 -- Three critical recommendations from a national workshop ...
... , WEDNESDAY, March 10 (HealthDay News) -- By analyzing ... U.S. scientists have identified gene mutations associated with the ... the limbs, hands and feet. , The study, published ... of Medicine , involved sequencing the complete genome of ...
... infestations, study shows, , WEDNESDAY, March 10 (HealthDay News)-- ... ivermectin is more effective than the standard treatment, the ... published in the March 11 issue of the ... percent of those treated with ivermectin were lice-free after ...
Cached Medicine News:Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight 2Health News:High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight 3Health News:Hot Tub Company Helps Swimmers Thaw and Supports Special Olympics 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 4Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 5Health News:Gene Mutations Identified for Charcot-Marie-Tooth Syndrome 2Health News:For Tough Head Lice, Pill Tops Lotion 2Health News:For Tough Head Lice, Pill Tops Lotion 3
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: